BOSTON--(BUSINESS WIRE)--Feb. 26, 2018--
Verastem, Inc. (NASDAQ:VSTM), focused on developing drugs to improve the
survival and quality of life of cancer patients, today announced that
the Company will present at the 30th Annual ROTH Conference
on Monday, March 12, 2018 at 4:30 pm PST in Dana Point, CA, USA.
A live webcast of the presentation will be available on the investors
section of the Company’s website at www.verastem.com.
An archived presentation will be available for 90 days.
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on
discovering and developing drugs to improve outcomes for patients with
cancer. Verastem is currently developing duvelisib, a dual inhibitor of
PI3K-delta and PI3K-gamma, which has successfully met its primary
endpoint in the Phase 2 study DYNAMO™ in iNHL and the Phase 3 clinical
trial DUO™ in patients with chronic lymphocytic leukemia/small
lymphocytic lymphoma (CLL/SLL). Verastem has submitted a New Drug
Application (NDA) requesting the full approval of duvelisib for the
treatment of patients with relapsed or refractory CLL/SLL, and
accelerated approval for the treatment of patients with relapsed or
refractory follicular lymphoma (FL). In addition, Verastem is developing
the FAK inhibitor defactinib, which is currently being evaluated in
three separate clinical collaborations in combination with
immunotherapeutic agents for the treatment of several different cancer
types, including pancreatic cancer, ovarian cancer, non-small cell lung
cancer, and mesothelioma. Verastem’s product candidates seek to treat
cancer by modulating the local tumor microenvironment, enhancing
anti-tumor immunity, and reducing cancer stem cells. For more
information, please visit www.verastem.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180226005124/en/
Source: Verastem, Inc.
Marianne M. Lambertson, 781-292-4273
President, Corporate Communications